安杰思：2025年净利润同比下降24.06%

Core Viewpoint - The company reported a decline in revenue and net profit for the year 2025, attributed to industry factors such as domestic medical insurance centralized procurement and overseas tariff policies, as well as increased competition in the minimally invasive endoscopic treatment sector [1] Financial Performance - The company's total operating revenue for 2025 was 597.21 million yuan, a decrease of 6.19% compared to the same period last year [1] - The net profit attributable to the parent company's owners was 222.82 million yuan, down 24.06% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 191.42 million yuan, reflecting a decline of 29.81% compared to the previous year [1] Industry Context - The medical device industry faced challenges due to domestic medical insurance centralized procurement and overseas tariff policies, impacting the company's main business [1] - Increased competition in the minimally invasive endoscopic treatment field has contributed to the company's performance pressure in 2025 [1]